Blood:Yap1-Scribble极化决定了造血干细胞的命运

2020-06-07 QQT MedSci原创

造血干细胞对应激的适应反应取决于Yap1/Taz;在HSC命运决定中,Scribble连接Cdc42和Hippo信号级联的胞质功能。

YAP1及其类似物Taz在很大程度上可控制上皮组织的生长。Althoff等已经确认造血干细胞(HSC)对应激的适应性反应取决于YAP1和Taz。

YAP1和Taz缺失可导致HSC静止丧失、对称的自我更新能力,使HSC更容易受到系列清髓性5-氟尿嘧啶治疗的影响。这一效应依赖于YAP1通过其PDZ结构域介导的与脚手架Scribble的相互作用而主导的胞浆极化。

Scrible和YAP1协同控制胞质Cdc42的活性和体内HSC的命运决定。Scribble缺失可破坏YAP1与Cdc42的共极化,减弱Cdc42的活性,从而导致具有竞争重建优势的自我更新中的HSC增多。

上述数据表明,Scribble/YAP1共极化对CdC42依赖的HSC不对称分裂和命运活性是必不可少的。Scribble、YAP1和Taz联合缺失可导致Rac特异性鸟嘌呤核苷酸交换因子的转录上调、Rac激活和HSC适应性恢复。Scrible将Cdc42与Hippo信号级联的胞浆功能联系在一起,决定了HSC的命运。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793694, encodeId=f04e1e93694e0, content=<a href='/topic/show?id=d1741606614' target=_blank style='color:#2F92EE;'>#Scrib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16066, encryptionId=d1741606614, topicName=Scrib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Feb 19 19:31:35 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081922, encodeId=622d2081922dc, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Wed Aug 19 23:31:35 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715758, encodeId=20631e1575889, content=<a href='/topic/show?id=24051893e0f' target=_blank style='color:#2F92EE;'>#YAP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18937, encryptionId=24051893e0f, topicName=YAP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941632034462, createdName=xinmeili, createdTime=Mon Dec 14 15:31:35 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025465, encodeId=570c102546586, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Wed Jun 10 21:31:35 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271518, encodeId=1f9412e15183f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494736, encodeId=32411494e363c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614867, encodeId=fa1a161486e98, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2021-02-19 wangbingxhy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793694, encodeId=f04e1e93694e0, content=<a href='/topic/show?id=d1741606614' target=_blank style='color:#2F92EE;'>#Scrib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16066, encryptionId=d1741606614, topicName=Scrib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Feb 19 19:31:35 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081922, encodeId=622d2081922dc, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Wed Aug 19 23:31:35 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715758, encodeId=20631e1575889, content=<a href='/topic/show?id=24051893e0f' target=_blank style='color:#2F92EE;'>#YAP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18937, encryptionId=24051893e0f, topicName=YAP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941632034462, createdName=xinmeili, createdTime=Mon Dec 14 15:31:35 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025465, encodeId=570c102546586, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Wed Jun 10 21:31:35 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271518, encodeId=1f9412e15183f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494736, encodeId=32411494e363c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614867, encodeId=fa1a161486e98, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2020-08-19 gujh
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793694, encodeId=f04e1e93694e0, content=<a href='/topic/show?id=d1741606614' target=_blank style='color:#2F92EE;'>#Scrib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16066, encryptionId=d1741606614, topicName=Scrib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Feb 19 19:31:35 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081922, encodeId=622d2081922dc, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Wed Aug 19 23:31:35 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715758, encodeId=20631e1575889, content=<a href='/topic/show?id=24051893e0f' target=_blank style='color:#2F92EE;'>#YAP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18937, encryptionId=24051893e0f, topicName=YAP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941632034462, createdName=xinmeili, createdTime=Mon Dec 14 15:31:35 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025465, encodeId=570c102546586, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Wed Jun 10 21:31:35 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271518, encodeId=1f9412e15183f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494736, encodeId=32411494e363c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614867, encodeId=fa1a161486e98, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2020-12-14 xinmeili
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793694, encodeId=f04e1e93694e0, content=<a href='/topic/show?id=d1741606614' target=_blank style='color:#2F92EE;'>#Scrib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16066, encryptionId=d1741606614, topicName=Scrib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Feb 19 19:31:35 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081922, encodeId=622d2081922dc, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Wed Aug 19 23:31:35 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715758, encodeId=20631e1575889, content=<a href='/topic/show?id=24051893e0f' target=_blank style='color:#2F92EE;'>#YAP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18937, encryptionId=24051893e0f, topicName=YAP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941632034462, createdName=xinmeili, createdTime=Mon Dec 14 15:31:35 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025465, encodeId=570c102546586, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Wed Jun 10 21:31:35 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271518, encodeId=1f9412e15183f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494736, encodeId=32411494e363c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614867, encodeId=fa1a161486e98, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2020-06-10 独孤立克

    干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1793694, encodeId=f04e1e93694e0, content=<a href='/topic/show?id=d1741606614' target=_blank style='color:#2F92EE;'>#Scrib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16066, encryptionId=d1741606614, topicName=Scrib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Feb 19 19:31:35 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081922, encodeId=622d2081922dc, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Wed Aug 19 23:31:35 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715758, encodeId=20631e1575889, content=<a href='/topic/show?id=24051893e0f' target=_blank style='color:#2F92EE;'>#YAP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18937, encryptionId=24051893e0f, topicName=YAP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941632034462, createdName=xinmeili, createdTime=Mon Dec 14 15:31:35 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025465, encodeId=570c102546586, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Wed Jun 10 21:31:35 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271518, encodeId=1f9412e15183f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494736, encodeId=32411494e363c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614867, encodeId=fa1a161486e98, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1793694, encodeId=f04e1e93694e0, content=<a href='/topic/show?id=d1741606614' target=_blank style='color:#2F92EE;'>#Scrib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16066, encryptionId=d1741606614, topicName=Scrib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Feb 19 19:31:35 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081922, encodeId=622d2081922dc, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Wed Aug 19 23:31:35 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715758, encodeId=20631e1575889, content=<a href='/topic/show?id=24051893e0f' target=_blank style='color:#2F92EE;'>#YAP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18937, encryptionId=24051893e0f, topicName=YAP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941632034462, createdName=xinmeili, createdTime=Mon Dec 14 15:31:35 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025465, encodeId=570c102546586, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Wed Jun 10 21:31:35 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271518, encodeId=1f9412e15183f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494736, encodeId=32411494e363c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614867, encodeId=fa1a161486e98, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=)]
    2020-06-09 俅侠
  7. [GetPortalCommentsPageByObjectIdResponse(id=1793694, encodeId=f04e1e93694e0, content=<a href='/topic/show?id=d1741606614' target=_blank style='color:#2F92EE;'>#Scrib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16066, encryptionId=d1741606614, topicName=Scrib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Feb 19 19:31:35 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081922, encodeId=622d2081922dc, content=<a href='/topic/show?id=c2971893397' target=_blank style='color:#2F92EE;'>#YAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18933, encryptionId=c2971893397, topicName=YAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3333505, createdName=gujh, createdTime=Wed Aug 19 23:31:35 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715758, encodeId=20631e1575889, content=<a href='/topic/show?id=24051893e0f' target=_blank style='color:#2F92EE;'>#YAP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18937, encryptionId=24051893e0f, topicName=YAP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941632034462, createdName=xinmeili, createdTime=Mon Dec 14 15:31:35 CST 2020, time=2020-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025465, encodeId=570c102546586, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Wed Jun 10 21:31:35 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271518, encodeId=1f9412e15183f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494736, encodeId=32411494e363c, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614867, encodeId=fa1a161486e98, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Jun 09 12:31:35 CST 2020, time=2020-06-09, status=1, ipAttribution=)]

相关资讯

Cell Death Dis:BCL-XL对于人红细胞生成及造血干细胞移植的重要作用

在发育过程及应激条件下,抗凋亡相关BCL-2蛋白家族(BCL-2、BCL-XL、MCL-1、A1和BCL-W)可抵消凋亡信号的出现,对所有细胞的生存都必不可少。虽然在小鼠模型中发现了多种不同细胞类型均有“ BCL-2依赖性”,但在人源细胞中,不同的抗凋亡BCL-2家族蛋白的作用的相关信息却报道的很少。本研究概述了BCL-XL对人造血细胞的存活及功能的作用,旨在预测新型BCL-XL抑制剂BH3类似物

Blood:EGFR依赖性的DNA修复促进造血再生

EGF通过激活DNA-PKcs和NHEJ促进HSC DNA修复和造血再生。 EGF在化疗后驱动造血细胞再生,并在放疗后促进人HSC恢复,同时增加HSC基因间突变

Blood:衰老诱导的IL27Ra信号可损伤造血干细胞

造血干细胞(HSC)衰老与骨髓增生相关疾病及免疫衰老的风险增加息息相关。

Blood:allo-HSCT后的长期存活者及其供体的克隆造血分析

克隆造血(CH),包括供体移植性CH,在供体和allo-HSCT后的长期存活者中非常普遍。CH克隆在造血系统的不同层次上不断扩展,并能进化为亚克隆。

Blood:CALR单倍剂量不足可增强造血干细胞的活性,参与MPN的发生

Calr缺乏会导致骨髓中的红细胞生成减少,脾内髓外造血功能降低。 CALR单倍剂量不足会恢复受CALR突变破坏的HSC的自我更新能力,这是MPN发生所必需的。